Abstract 280P
Background
Multiple studies in the past have elaborated the role of different risks stratification scores such as Sokal, Hasford, and Eutos (S.H.E.). These studies either correlated the risk stratification with survival, PFS, CcyR, MMR, or point BCR-ABL at different time intervals post-TKI. However, as we understand, all patients do not have a similar disease burden at the initiation of TKI. Also, using cut off level for different age group, gender, and disease burdens is an oversimplification of the disease remission criteria. There are very few studies on the rate (velocity) of the fall of BCR-ABL. The aim of this study was to compare the efficacy of various prognostic score in predicting the fall in BCR ABL over two years.
Methods
This is a prospective observational study comprising 653 (sample size predicted: 300) patients managed at a tertiary care center in north India based on a uniform treatment and evaluation protocol (Generic Imatinib 400 mg OD and three monthly RQ-PCR-BCR/ABL-IS). Statistics were done using Python-13.
Results
The median age of the study population was 43 years (16-87). On comparing the three risk groups of Sokal, the high-risk patients had the least fall in BCR-ABL at any time point up to 2 years post intiation of TKI. Whereas, there was no difference between low and intermediate risk. The difference in the three groups was not statistically significant. There was also no statistically significant difference in the rate of fall of BCR/ABL in the three risk groups of Hasford. The two risk groups of Eutos score had a significant difference in the rate of fall of BCR/ABL, the high risk having a lower rate in comparison to low risk.
Conclusions
Of the three scoring systems, the EUTOS score outperforms as a prognostic model using rate of fall of BCR-ABL in newly diagnosed CML-CP patients upto two years on Generic Imatinib.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
NA.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
97P - The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer
Presenter: Jong Hoon Lee
Session: Poster display session
Resources:
Abstract
98P - Influence of DPYD*9, DPYD*6 and GSTP1 ile105val genetic polymorphisms on capecitabine and oxaliplatin (CAPOX) associated toxicities in colorectal cancer patients
Presenter: Ashok Varma
Session: Poster display session
Resources:
Abstract
99P - Patient-derived tumour model by new culture method leading to the precision medicine
Presenter: Norikatsu Miyoshi
Session: Poster display session
Resources:
Abstract
100P - Clinical impact and carcinogenic mechanism of NCAPG overexpression in colon cancer
Presenter: Kai-Yuan Lin
Session: Poster display session
Resources:
Abstract
101P - Combined cellular immunotherapy and chemotherapy improves clinical outcome and displays safety in the treatment of patients with colorectal cancer
Presenter: Chang Wang
Session: Poster display session
Resources:
Abstract
102P - Clinical features of anorectal cancer in patients with Crohn’s disease: Japanese single center study
Presenter: Kazuhiro Watanabe
Session: Poster display session
Resources:
Abstract
103P - Contrast-enhanced CT-based textural parameters as potential prognostic factors of survival for colorectal cancer patients receiving targeted therapy
Presenter: Yanfei Yang
Session: Poster display session
Resources:
Abstract
104P - Prognostic significance of tumour location to the oncologic outcome of colon cancer
Presenter: Sare Hosseini
Session: Poster display session
Resources:
Abstract
105P - Detection and clinical significance of circulating tumour cells in patients with rectal cancer
Presenter: Shuohui Dong
Session: Poster display session
Resources:
Abstract
106P - The risk of malignization incidence in patients with polyps and polyposis of the colon and rectum
Presenter: Yakov Ten
Session: Poster display session
Resources:
Abstract